Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $9.1 million.

  • Maravai Lifesciences Holdings' Share-based Compensation fell 3060.54% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year decrease of 2368.5%. This contributed to the annual value of $49.4 million for FY2024, which is 4286.75% up from last year.
  • As of Q3 2025, Maravai Lifesciences Holdings' Share-based Compensation stood at $9.1 million, which was down 3060.54% from $6.8 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year Share-based Compensation high stood at $13.8 million for Q2 2024, and its period low was $2.2 million during Q4 2021.
  • In the last 5 years, Maravai Lifesciences Holdings' Share-based Compensation had a median value of $6.8 million in 2025 and averaged $7.3 million.
  • The largest annual percentage gain for Maravai Lifesciences Holdings' Share-based Compensation in the last 5 years was 34842.52% (2021), contrasted with its biggest fall of 8972.16% (2021).
  • Quarter analysis of 5 years shows Maravai Lifesciences Holdings' Share-based Compensation stood at $2.2 million in 2021, then surged by 168.83% to $6.0 million in 2022, then soared by 55.83% to $9.3 million in 2023, then rose by 12.88% to $10.5 million in 2024, then fell by 14.12% to $9.1 million in 2025.
  • Its last three reported values are $9.1 million in Q3 2025, $6.8 million for Q2 2025, and $10.4 million during Q1 2025.